Contents 2 min read

Claim and source comparison

Phenylpiracetam: a mouse behavioral experiment and the 2026 WADA List.

· Bounded source comparison; not a complete clinical review or independent medical endorsement.

Animal study

Zvejniece et al. (2011) compared R and S phenylpiracetam enantiomers in mice; memory responses differed by isomer. This preclinical trial does not establish 20–60-fold superiority to piracetam in humans or clinical benefits via DAT/NET.

The experiment compared R and S isomers in mice. It does not establish effective human doses, adverse-effect rates or tolerance duration.

Source 2 · Abstract read

Regulatory scientific assessment

WADA’s 2026 list prohibits fonturacetam [4-phenylpiracetam (carphedon)] in competition under S6.A stimulants. A prohibited-list entry is not evidence of clinical efficacy or safety in healthy people.

This classification concerns the 2026 competition rules. It does not establish clinical efficacy, safe use or medicine approval in other countries.

Source 3 · Official summary read

Our evidence and source methodology

Phenylpiracetam: conceptual editorial illustration
Conceptual editorial artwork; not a research finding or evidence of clinical benefit in humans.

What is Phenylpiracetam?

Phenylpiracetam is a synthetic racetam. Stimulant and memory mechanisms have been studied in animals; cognitive superiority or a safe cycling regimen in healthy people has not been established.

Mechanism of Effect

Zvejniece et al. (2011) compared R and S phenylpiracetam enantiomers in mice; memory responses differed by isomer. This preclinical trial does not establish 20–60-fold superiority to piracetam in humans or clinical benefits via DAT/NET.

Clinical Evidence

The experiment compared R and S isomers in mice. It does not establish effective human doses, adverse-effect rates or tolerance duration.

WADA’s 2026 list prohibits fonturacetam [4-phenylpiracetam (carphedon)] in competition under S6.A stimulants. A prohibited-list entry is not evidence of clinical efficacy or safety in healthy people.

⚠ Tolerance and Limited Evidence Warning

There is insufficient clinical evidence that a particular break or cycling schedule prevents tolerance or improves efficacy and safety.

Dose information and research limits

This dose information describes research or product context; it is not a personal prescription, established safe upper limit or efficacy guarantee for healthy people. Extracts and different formulations should not be treated as equivalent milligram for milligram.

Safety and Side Effects

The animal experiment reviewed here does not establish human adverse-effect or interaction rates for phenylpiracetam. A validated personal dose or cycling protocol is unavailable.

Sources

  1. Malykh AG & Sadaie MR (2010). Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders. Drugs, 70(3), 287–312. PubMed · PMID 20166767
  2. Zvejniece L, et al. (2011). Investigation into stereoselective pharmacological activity of phenotropil. Basic & Clinical Pharmacology & Toxicology, 109(5), 407–412. PubMed · PMID 21689376
  3. World Anti-Doping Agency. The 2026 Prohibited List. https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf World Anti-Doping Agency

Link verification checks the identity of the publication; it does not constitute independent expert review of clinical claims. Our evidence and source methodology · Source directory

Frequently Asked Questions